Brief: Insmed Provides Clinical And Business Update
17/12/2025 21:03
Dec 17 (Reuters) - Insmed Inc INSM.O: INSMED PROVIDES CLINICAL AND BUSINESS UPDATE INSMED INC - PHASE 2B BIRCH STUDY OF BRENSOCATIB IN CRSSNP DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTS INSMED INC - DISCONTINUES CRSSNP PROGRAM INSMED INC - ACQUIRES PHASE 2 READY MONOCLONAL ANTIBODY FOR POTENTIAL RESPIRATORY AND IMMUNOLOGICAL & INFLAMMATORY INDICATIONS Source text: ID:nPnyHpg0a Further company coverage: INSM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insmed Incorporated
See all newsBrief: Insmed Launches Brinsupri® Tablets 25 Mg (Brensocatib Hydrate) For The Treatment Of Non-Cystic Fibrosis Bronchiectasis In Japan
Brief: Insmed Incorporated - Launches Four Pivotal Phase 3 Studies For TPIP In Pulmonary Diseases
U.S. STOCKS ON THE MOVE-Nike, Synopsys, Intel
Insmed CFO Sara Bonstein steps down; shares fall
U.S. STOCKS ON THE MOVE- Cenovus Energy, TeraWulf, Alector